Dronabinol/palmidrol
 | |
 | |
| Combination of | |
|---|---|
| Dronabinol | Cannabinoid CB1 and CB2 receptor agonist |
| Palmidrol | Endocannabinoid-like fatty acid amide |
| Clinical data | |
| Other names | Dronabinol/palmitoylethanolamide; Δ9-Tetrahydrocannabinol/palmitoylethanolamide; Δ9-THC/PEA; SCI-110; SCI110; THX-OSA01; THX-OSA01; THX-RS01; THX-110; THX110; THX-TS01 |
| Routes of administration | Oral[1] |
Dronabinol/palmidrol (developmental code names SCI-110, THX-OSA01, THX-RS01, THX-110, and THX-TS01), also known as Δ9-tetrahydrocannabinol/palmitoylethanolamide (THC/PEA), is a combination of dronabinol (Δ9-THC), a cannabinoid CB1 and CB2 receptor agonist, and palmidrol (palmitoylethanolamide; PEA), an endocannabinoid-like fatty acid amide with various cannabidiol (CBD)-like actions, which is under development for the treatment of agitation, Alzheimer's disease, Tourette's syndrome, and sleep apnea syndrome.[1][2][3][4][5] It was also under development for treatment of back pain, but development for this indication was discontinued.[1] The drug is taken orally.[1] It is thought that palmidrol may enhance the effectiveness and tolerability compared to dronabinol alone.[4] The drug was originated by Therapix Biosciences and is being developed by SciSparc.[1][2] As of September 2025, the drug is in phase 2 clinical trials for all active indications.[1][2]
See also
References
- 1 2 3 4 5 6 "Dronabinol+palmitoylethanolamide". AdisInsight. 2 September 2025. Retrieved 1 June 2026.
- 1 2 3 "Delving into the Latest Updates on Dronabinol/Palmidrol with Synapse". Synapse. 7 May 2026. Retrieved 1 June 2026.
- ↑ Clayton P, Subah S, Venkatesh R, Hill M, Bogoda N (2023). "Palmitoylethanolamide: A Potential Alternative to Cannabidiol". Journal of Dietary Supplements. 20 (3): 505–530. doi:10.1080/19390211.2021.2005733. PMID 34842030.
- 1 2 Häge A, Krämer R, Dunlap M, Mechler K, Müller-Vahl KR, Nagy P (June 2025). "Emerging therapeutic approaches for Tourette syndrome and other tic disorders - a systematic review of current clinical trials". European Child & Adolescent Psychiatry. 34 (6): 1719–1729. doi:10.1007/s00787-024-02637-x. PMID 39714607.
Furthermore, different cannabis-based approaches are being investigated including dronabinol (tetrahydrocannabiniol (THC)) in combination with palmitoylethanolamide (PEA) as well as pure cannabidiol (CBD) – also known as Epidiolex® or Epidyolex® - and an oral oily cannabis extract with a ratio of THC: CBD at 10:15. It is believed that combinations of THC with either PEA or CBD may cause an "entourage effect" resulting in increased efficacy and reduced adverse effects compared to pure THC [28].
- ↑ Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF (2021). "A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette's Syndrome". The Journal of Neuropsychiatry and Clinical Neurosciences. 33 (4): 328–336. doi:10.1176/appi.neuropsych.19080178. PMID 34340527.